This company has been marked as potentially delisted and may not be actively trading. NASDAQ:VVUS VIVUS (VVUS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About VIVUS Stock (NASDAQ:VVUS) 30 days 90 days 365 days Advanced Chart Get VIVUS alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.26▼$0.4752-Week Range N/AVolume2.03 million shsAverage Volume1.44 million shsMarket Capitalization$7.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA. Read More Receive VVUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for VIVUS and its competitors with MarketBeat's FREE daily newsletter. Email Address VVUS Stock News HeadlinesVIVUS Announces Enrollment of First Patient in Phase 2 Clinical Trial Assessing Ethanol-Free Carmustine as a Component of High-Dose Chemotherapy Prior to Transplant in Patients with Hodgkin or Non-Hodgkin LymphomaApril 14, 2025 | globenewswire.comVIVUS' QSYMIA® to be Featured on Health Uncensored with Dr. DrewMarch 19, 2025 | globenewswire.comThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself. | American Alternative (Ad)VIVUS Launches QSYMIA® in the United Arab EmiratesMarch 10, 2025 | globenewswire.comVIVUS Unveils Global Initiative to Advance Healthy and Sustainable Weight ManagementMarch 4, 2025 | globenewswire.comVIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025January 13, 2025 | globenewswire.comVIVUS Shares Significant Regulatory Update on QSYMIA®October 28, 2024 | globenewswire.comVIVUS Announces Label Update for QSYMIA®October 23, 2024 | tmcnet.comSee More Headlines VVUS Stock Analysis - Frequently Asked Questions How were VIVUS's earnings last quarter? VIVUS, Inc. (NASDAQ:VVUS) announced its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, beating the consensus estimate of ($0.80) by $0.31. The biopharmaceutical company earned $19.63 million during the quarter. When did VIVUS's stock split? VIVUS shares reverse split on the morning of Tuesday, September 11th 2018.The 1-10 reverse split was announced on Monday, September 10th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 10th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of VIVUS own? Based on aggregate information from My MarketBeat watchlists, some other companies that VIVUS investors own include Fulcrum Therapeutics (FULC), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL), Advanced Micro Devices (AMD), Novavax (NVAX), CymaBay Therapeutics (CBAY) and Amarin (AMRN). Company Calendar Last Earnings5/06/2020Today8/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:VVUS CIK881524 Webwww.vivus.com Phone(650) 934-5200FaxN/AEmployees57Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$31.50 million Net Margins-39.28% Pretax MarginN/A Return on EquityN/A Return on Assets-12.18% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.28 Sales & Book Value Annual Sales$69.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($6.50) per share Price / BookN/AMiscellaneous Outstanding Shares17,867,000Free FloatN/AMarket Cap$7.33 million OptionableOptionable Beta-0.84 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:VVUS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VIVUS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VIVUS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
